Their main product candidate, Hematide, is currently in Phase 3 trials for the treatment of anemia associated with chronic renal failure. Anemia is a condition characterized by a deficiency of red blood cells and hemoglobin, commonly found in patients with chronic renal failure, cancer, heart failure, and other critical illnesses. Affymax's first product candidate, peginesatide, is being reviewed by the FDA for the treatment of anemia associated with chronic kidney disease in adult patients on dialysis.